Nurix Therapeutics
Price & Volume
Stats
See more52W Range | $7.65-$29.56 |
Market Cap | $1.4B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $56.4M |
Revenue Growth (YoY) | -31.8% |
Gross Profit (12 Mos) | -$145.8M |
Diluted EPS | -$2.90 |
News
See moreYahoo Finance • last year
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
Yahoo Finance • last year
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm
Yahoo Finance • last year
Nurix Therapeutics to Participate in Upcoming Investor Conferences
About
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Address | 1700 Owens Street, San Francisco, CA, United States, 94158 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 284 |
